title: The basolateral amygdala and nucleus accumbens core mediate dissociable aspects of drug memory reconsolidation.
abstract: A distributed limbic-corticostriatal circuitry is implicated in cue-induced drug craving and relapse. Exposure to drug-paired cues not only precipitates relapse, but also triggers the reactivation and reconsolidation of the cue-drug memory. However, the limbic cortical-striatal circuitry underlying drug memory reconsolidation is unclear. The aim of this study was to investigate the involvement of the nucleus accumbens core and the basolateral amygdala in the reconsolidation of a cocaine-conditioned stimulus-evoked memory. Antisense oligodeoxynucleotides (ASO) were infused into each structure to knock down the expression of the immediate-early gene zif268, which is known to be required for memory reconsolidation. Control infusions used missense oligodeoxynucleotides (MSO). The effects of zif268 knockdown were measured in two complementary paradigms widely used to assess the impact of drug-paired CSs upon drug seeking: the acquisition of a new instrumental response with conditioned reinforcement and conditioned place preference. The results show that both intranucleus accumbens core and intrabasolateral amygdala zif268 ASO infusions at memory reactivation impaired the reconsolidation of the memory underlying a cocaine-conditioned place preference. However, knockdown of zif268 in the nucleus accumbens at memory reactivation had no effect on the memory underlying the conditioned reinforcing properties of the cocaine-paired CS measured subsequently, and this is in contrast to the marked impairment observed previously following intrabasolateral amygdala zif268 ASO infusions. These results suggest that both the basolateral amygdala and nucleus accumbens core are key structures within limbic cortical-striatal circuitry where reconsolidation of a cue-drug memory occurs. However reconsolidation of memory representations formed during Pavlovian conditioning are differentially localized in each site.
authors.affiliation: Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom.
authors.forename: Florence R M
authors.initials: FR
authors.lastname: Théberge
authors.forename: Amy L
authors.initials: AL
authors.lastname: Milton
authors.forename: David
authors.initials: D
authors.lastname: Belin
authors.forename: Jonathan L C
authors.initials: JL
authors.lastname: Lee
authors.forename: Barry J
authors.initials: BJ
authors.lastname: Everitt
mesh_terms: D000679:Amygdala / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology*; D003463:Cues; D058999:Drug-Seeking Behavior / Q000187:drug effects / Q000502:physiology*; D051766:Early Growth Response Protein 1 / Q000378:metabolism*; D055785:Gene Knockdown Techniques; D011939:Mental Recall / Q000187:drug effects / Q000502:physiology; D008845:Microinjections; D009434:Neural Pathways / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D020319:Oligodeoxyribonucleotides, Antisense / Q000008:administration & dosage; D051381:Rats; D011919:Rats, Inbred Strains; D012153:Retention, Psychology / Q000187:drug effects / Q000502:physiology*
chemical_list: D000697:Central Nervous System Stimulants; D051766:Early Growth Response Protein 1; C486110:Egr1 protein, rat; D020319:Oligodeoxyribonucleotides, Antisense; D003042:Cocaine
references.citation: Neuropsychopharmacology. 2008 May;33(6):1413-25
references.pmid: 17712353
references.citation: Physiol Behav. 2005 Dec 15;86(5):717-30
references.pmid: 16257019
references.citation: NIDA Res Monogr. 1988;84:25-43
references.pmid: 3147384
references.citation: J Neurosci. 2006 Dec 6;26(49):12694-9
references.pmid: 17151272
references.citation: Behav Pharmacol. 1996 Dec;7(8):754-763
references.pmid: 11224470
references.citation: Ann N Y Acad Sci. 1999 Jun 29;877:412-38
references.pmid: 10415662
references.citation: Neuroscience. 1991;42(1):1-18
references.pmid: 1830641
references.citation: Psychopharmacology (Berl). 1981;75(2):134-43
references.pmid: 6798603
references.citation: Learn Mem. 2006 Sep-Oct;13(5):498-505
references.pmid: 17015846
references.citation: Curr Opin Neurobiol. 2006 Apr;16(2):174-8
references.pmid: 16563730
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):44-56
references.pmid: 12652346
references.citation: J Neurosci. 2006 Mar 15;26(11):3010-20
references.pmid: 16540579
references.citation: Learn Mem. 2008 Jan 29;15(2):88-92
references.pmid: 18235109
references.citation: Trends Neurosci. 2003 Feb;26(2):65-72
references.pmid: 12536129
references.citation: J Neurosci. 2003 Apr 15;23(8):3531-7
references.pmid: 12716962
references.citation: Neuron. 2005 Sep 15;47(6):873-84
references.pmid: 16157281
references.citation: Learn Mem. 2007 January-February;14(1):36-46
references.pmid: 17272651
references.citation: Neuroscience. 1999;93(4):1359-67
references.pmid: 10501460
references.citation: Biol Psychiatry. 2009 Feb 1;65(3):249-57
references.pmid: 18708183
references.citation: J Neurosci. 2008 Jul 2;28(27):6950-9
references.pmid: 18596169
references.citation: J Neurosci. 2006 May 31;26(22):5881-7
references.pmid: 16738229
references.citation: Behav Brain Res. 2003 Jun 16;142(1-2):17-30
references.pmid: 12798262
references.citation: Addiction. 2002 Feb;97(2):155-67
references.pmid: 11860387
references.citation: Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:66A-67A
references.pmid: 1498991
references.citation: Psychopharmacology (Berl). 2005 Apr;179(1):164-71
references.pmid: 15619119
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4321-6
references.pmid: 10760299
references.citation: J Exp Psychol Anim Behav Process. 1996 Jan;22(1):32-42
references.pmid: 8568495
references.citation: J Neurosci. 2001 Dec 15;21(24):9724-32
references.pmid: 11739581
references.citation: Eur J Neurosci. 2001 May;13(10):1984-92
references.pmid: 11403692
references.citation: Nat Neurosci. 2009 Mar;12(3):256-8
references.pmid: 19219038
references.citation: Prog Neurobiol. 1980;14(2-3):69-97
references.pmid: 6999537
references.citation: Psychopharmacology (Berl). 1998 Jan;135(2):151-60
references.pmid: 9497020
references.citation: J Pharmacol Exp Ther. 2006 Jun;317(3):1178-87
references.pmid: 16507711
references.citation: Behav Neurosci. 1993 Feb;107(1):3-22
references.pmid: 8447956
references.citation: Learn Mem. 2007 Jan 03;14(1-2):47-53
references.pmid: 17202429
references.citation: Neuroscience. 1989;30(1):77-86
references.pmid: 2664556
references.citation: Neurosci Biobehav Rev. 2002 May;26(3):321-52
references.pmid: 12034134
references.citation: Eur J Neurosci. 2006 Jun;23(11):3071-80
references.pmid: 16819997
references.citation: Trends Neurosci. 2009 Aug;32(8):413-20
references.pmid: 19640595
references.citation: Eur J Neurosci. 2003 May;17(9):1964-72
references.pmid: 12752796
references.citation: Learn Mem. 2008 Aug 06;15(8):597-602
references.pmid: 18685151
references.citation: Science. 2004 May 7;304(5672):839-43
references.pmid: 15073322
references.citation: Behav Brain Res. 2006 Aug 10;171(2):329-37
references.pmid: 16698095
references.citation: Neuron. 2005 Sep 15;47(6):795-801
references.pmid: 16157275
references.citation: J Psychiatr Res. 2008 May;42(6):503-6
references.pmid: 17588604
references.citation: Neuropharmacology. 2004;47 Suppl 1:202-13
references.pmid: 15464138
references.citation: Behav Brain Res. 1993 Jun 30;55(2):269-81
references.pmid: 8357530